- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Need for Prompt Epinephrine Use in Anaphylaxis
A panelist discusses how anaphylaxis should be defined and treated promptly with epinephrine, highlighting the concerning statistic that not all patients who experience anaphylaxis receive this critical first-line treatment.
EP: 1.Need for Prompt Epinephrine Use in Anaphylaxis
EP: 2.Why Epinephrine Is the Gold Standard in Treating Anaphylaxis
EP: 3.Addressing Barriers to Epinephrine Use: From Reluctance to Readiness
EP: 4.Challenges with Epinephrine Autoinjectors
EP: 5.Epinephrine Nasal Spray: A Leap Forward in Anaphylaxis Care
EP: 6.Oral Food Challenge (OFC) Study with Epinephrine Nasal Spray
EP: 7.Clinical Perspectives on Real-World Utility and Impact of Epinephrine Nasal Spray
EP: 8.Real-World Case Examples: The Impact of Epinephrine Nasal Spray
EP: 9.Closing Thoughts on Treating Anaphylaxis with Epinephrine Nasal Spray
Video content above is prompted by the following:
Amar Dixit, MD, MBA, FACAAI, FAAAI, a board-certified allergist and immunologist, opens the presentation "Beyond the Needle: Promoting Prompt Anaphylaxis Treatment." He outlines key objectives: discussing timely epinephrine administration, identifying challenges with epinephrine use, applying strategies for patient education, and exploring intranasal epinephrine's potential. A polling question reveals 60% of attendees frequently encounter patients at risk of Type 1 allergic reactions, confirming the topic's relevance to their practices.
Dr. Dixit explains the significant prevalence of Type 1 allergic reactions, affecting 35-45 million Americans and causing over 500,000 ER visits annually. He defines anaphylaxis as either severe single-system involvement (skin, respiratory, or cardiovascular) or any two-system involvement regardless of severity. This definition aims to encourage earlier treatment with epinephrine rather than waiting until symptoms become life-threatening.
The presentation highlights that while 85% of anaphylaxis cases involve mucocutaneous symptoms and 80% involve respiratory symptoms, there remains a troubling gap in treatment. Even among pediatric patients who receive epinephrine in emergency departments, not all receive this life-saving medication promptly. Dr. Dixit emphasizes that every patient experiencing anaphylaxis should receive immediate epinephrine administration, as delays can result in preventable fatalities.
